In the past 52-week period, shares of Myriad Genetics, Inc. (NASDAQ:MYGN) have moved within the range of $15.15 to $37.30. On the stock’s most recent trading day, the company’s shares ended the regular session at $33.69, which is 9.68% lower than its 52-week high.
Myriad Genetics, Inc. (MYGN) has demonstrated a 20-day simple moving average (SMA) of -6.41%, and a 50-day SMA of 1.77%. This public company’s current market capitalization stands at $2.32 billion.
Analyzing Consensus Estimates, Sales Revenue and Net Income
Gauging the level of enthusiasm that Wall Street analysts have for a particular stock is important when considering an investment. According to the latest data, the consensus recommendation for Myriad Genetics, Inc. (MYGN) is Hold.
When it comes to reporting sales figures, public companies typically post earnings and revenue that fall above or below the average Wall Street forecast. In the most recent quarterly financial report, for the quarter ending Jun. 2017, Myriad Genetics, Inc. (MYGN) delivered a 3.49% surprise with its net revenue. Sales reached $0.2 billion during the three-month period, compared to the average analyst estimate of $0.19 billion.
Meanwhile, during the same quarter Myriad Genetics, Inc. (MYGN) delivered a 17.46% earnings surprise. Net earnings for the quarter were posted at $0.30 per share, whereas Wall Street had forecast $0.26 per share.
Ownership at Myriad Genetics, Inc. (MYGN), According to Most Recent SEC Filings
A publicly-traded company’s most recent 13F filings give us important details about the organization’s institutional ownership. Myriad Genetics, Inc. (MYGN) has 0.07 billion shares outstanding currently, 115.43% of which belong to institutional investors. Those institutional holdings amount to $2.7 billion.
Additionally, according to the most recent 13F filing from Myriad Genetics, Inc. (MYGN), there were 38 new positions totaling 1,289,390 shares of the company’s stock. There were 31 sold out positions, on the other hand, totaling 2,516,560 shares.
Short, Medium and Long Term Indicators
Taking a look at a stock’s average volume – in the long, medium and short terms – is helpful for understanding investor sentiment and trading activity. Myriad Genetics, Inc. (MYGN) has had a 20-day average volume of 781,710 shares, with an average of 60% of short term indicators pointed at Sell.
The stock’s 50-day average volume has been 871,258 shares, with an average of 25% of medium term indicators pointing toward Buy. Finally, its 100-day average volume is 985,266 shares with 67% of long-term indicators pointing to Buy.